Serlopitant

Phase 3Small molecule

VVyne Therapeutics Inc.

Serlopitant is one of 122 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Chronic CoughActive, not recruiting

Prurigo NodularisActive, not recruiting

Epidermolysis BullosaActive, not recruiting

PsoriasisPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Chronic CoughPhase 2

Active, not recruiting

Prurigo NodularisPhase 3

Active, not recruiting

Epidermolysis BullosaPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Serlopitant

VVyne Therapeutics Inc.

Phase 3

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Raptiva

Roche

Preclinical

10 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Victoza

Novo Nordisk

Preclinical

2 10

Olux

HHarrow Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pruritus3 trials

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

Terminated·VVyne Therapeutics Inc.·Phase 2·NCT02975271·1 enrolled

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Completed·VVyne Therapeutics Inc.·Phase 2·NCT03841331·233 enrolled

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Terminated·VVyne Therapeutics Inc.·Phase 3·NCT03540160·558 enrolled

Prurigo Nodularis3 trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Completed·VVyne Therapeutics Inc.·Phase 3·NCT03677401·295 enrolled

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Completed·VVyne Therapeutics Inc.·Phase 3·NCT03546816·285 enrolled

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Completed·VVyne Therapeutics Inc.·Phase 2·NCT02196324·128 enrolled

Atopic Dermatitis1 trial

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Completed·VVyne Therapeutics Inc.·Phase 2·NCT02975206·484 enrolled

Epidermolysis Bullosa1 trial

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Completed·SStanford University·Phase 2·NCT03836001·28 enrolled

Psoriasis1 trial

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Completed·VVyne Therapeutics Inc.·Phase 2·NCT03343639·204 enrolled

1 more indication

Chronic Cough1 trial

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Completed·VVyne Therapeutics Inc.·Phase 2·NCT03282591·185 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Serlopitant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Serlopitant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Serlopitant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vyne Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVyne Therapeutics Inc.

Serlopitant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pruritus3 trials

Prurigo Nodularis3 trials

Atopic Dermatitis1 trial

Epidermolysis Bullosa1 trial

Psoriasis1 trial

Chronic Cough1 trial

References

Drug Info

Quick Facts

Related News